文章基本信息

标题：Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis
本地全文：下载
作者：Klara Asplund Högelin ; Nicolas Ruffin ; Elisa Pin 等
期刊名称：iScience
印刷版ISSN：2589-0042
出版年度：2021
卷号：24
期号：9
页码：1-21
DOI：10.1016/j.isci.2021.103078
语种：English
出版社：Elsevier
摘要：SummaryB cell depleting therapies (BCDTs) are widely used as immunomodulating agents for autoimmune diseases such as multiple sclerosis. Their possible impact on development of immunity to severe acute respiratory syndrome virus-2 (SARS-CoV-2) has raised concerns with the coronavirus disease 2019 (COVID-19) pandemic. We here evaluated the frequency of COVID-19-like symptoms and determined immunological responses in participants of an observational trial comprising several multiple sclerosis disease modulatory drugs (COMBAT-MS; NCT03193866) and in eleven patients after vaccination, with a focus on BCDT. Almost all seropositive and 17.9% of seronegative patients on BCDT, enriched for a history of COVID-19-like symptoms, developed anti-SARS-CoV-2 T cell memory, and T cells displayed functional similarity to controls producing IFN-γ and TNF. Following vaccination, vaccine-specific humoral memory was impaired, while all patients developed a specific T cell response. These results indicate that BCDTs do not abrogate SARS-CoV-2 cellular memory and provide a possible explanation as to why the majority of patients on BCDTs recover from COVID-19.Graphical abstractDisplay OmittedHighlights•BCDT might blunt antibody responses after COVID-19 infection or vaccination•Patients with no detectable B cells in the blood might still produce antibodies•A majority of patients that do not develop antibodies still display a T cell response•SARS-CoV-2 T-cells produce Th1 cytokines both in patients on BCDT and untreatedImmunology; Virology